By Sarah Karlin / Email the Author / Jul. 17, 2013
Executive Summary
No mention of affects to Medicare , Medicaid in the CBO score for the Senate compounding and supply chain bill, but FDA is likely to need more budget authority given that expected user fee revenues are not expected to cover the full costs of the new programs.
No comments:
Post a Comment